ORIGINAL ARTICLEWide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension
Section snippets
Clinicians' Evaluations of NYHA/WHO Functional Class
We evaluated agreement between clinicians in their assessment of NYHA/WHO functional class by presenting information about 10 hypothetical patients with PAH (eAppendix online linked to this article). The patients described were selected to represent a range of PAH severity. Because the goal was to assess whether clinicians approached functional class in the same manner, no “gold standard” or “correct” method of determining functional class was assumed; a “correct” functional class ranking for
Clinician Participants
A total of 113 clinicians participated in the 2 evaluations (Table 1). The initial paper administration involved 28 physicians and 16 nurses; 40 physicians and 29 nurses completed the online version. An additional 6 physicians who completed the online evaluation indicated that they had also participated in the initial paper version and thus were excluded from the second analysis. All participants indicated that they were actively involved in the clinical care of patients with PAH. In the
DISCUSSION
We found a wide variation in the NYHA/WHO functional class assessments made by clinicians who care for and conduct clinical research in patients with PAH. The findings were consistent in 2 independent groups of clinicians assessed with paper and online presentations of patients with PAH. Agreement on a single functional class was not seen for any patient, and in most cases judgments spanned 2 or 3 classes. Consistent with the discrepant conclusions reached was the reported wide variation in
CONCLUSION
We observed a wide variation in the NYHA/WHO functional class assignments made by both physicians and nurses for descriptions of patients with PAH. Despite the wide use of the NYHA/WHO functional class in clinical care and as a research tool, interrater agreement may be inadequate. Our findings further suggest potential systematic differences in clinicians' approach, such that some routinely rank patients in higher (or lower) functional class than do other practitioners. Regardless of whether a
REFERENCES (21)
- et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
Chest
(2007) - et al.
Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease
Heart Lung
(2002) - et al.
Assessment of functional status in patients with cardiac disease
Heart Lung
(1998) - et al.
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology
Am Heart J
(2007) The value of approved therapies for pulmonary arterial hypertension [editorial]
Am Heart J
(2007)- et al.
Kappa coefficients in epidemiology: an appraisal of a reappraisal
J Clin Epidemiol
(1988) - et al.
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
The New York Heart Association Classes and functional status: what are we really measuring?
Heart Lung
(2006) - et al.
Classification and prognosis of pulmonary arterial hypertension
Cited by (86)
Severity of precapillary pulmonary hypertension: Predictive factor
2023, PulmonologyCitation Excerpt :Cardiac catheterization confirmed a great variation in the hemodynamic severity of pulmonary vascular disease, strengthening the statistical correlation study.10 The patients were predominantly in the WHO/NYHA functional class III, and there was a great variation in PVR, noting with reservations a possible association of these functional classes with the hemodynamic severity of PHprecapillary and, thus, highlighting the need to include other non-invasive parameters in the evaluation of these patients.12 The RV measurement as a marker of hemodynamic severity was the objective of this study since the RV could be easily measured even with the use of other imaging techniques and on account of reproducibility of results with minor variation between observers, which was 5% in our echocardiography center.
Response
2023, ChestProviders’ assignment of NYHA functional class in patients with heart failure: A vignette study
2022, Heart and LungCitation Excerpt :The NYHA-FC has been called into question due to the subjectivity of the patient's reporting of their functionality and symptoms and the provider's interpretation of the reporting of symptoms.25 All of the variability with interpreting functionality can make determining NYHA-FC in patients with HF difficult especially when comorbid conditions are present which can confound presenting HF symptoms.25,27 In our study, we found that factors such as type of provider, number of patients seen weekly and if the provider assigned a HF Stage influenced accuracy in assigning NYHA-FC.
Interobserver agreement of the anatomic and physiological classification system for adult congenital heart disease
2020, American Heart JournalCitation Excerpt :There have been a couple of early attempts to assess the prognostic value of the proposed AP classification scheme,7,8 but this is the first study of its agreement and reliability. The study design used here mirrors IRR assessments of similar classification systems, including New York Heart Association Functional Class (NYHA FC).23,24 NYHA FC also incorporates both subjective and objective measures of patient status, and studies have found variable reliability, with clinician agreement ranging from 35.7% to 80.5%.
Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure
2020, Heart Failure Clinics
Dr Taichman has received research support from Actelion for participation in REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management). Dr McGoon has received grant support from Gilead and serves on a data safety and management/clinical end point committee for Actelion. Dr Sager has served as a consultant for Actelion and Gilead and has received research support from Acetelion. Dr Palevsky has served as a consultant for Actelion and Gilead.